Oncolytics Biotech updated efficacy from the phase 1 REO 022 study of pelareorep (Reolysin) combined with bevacizumab and FOLFIRI in second-line KRAS-mutant, microsatellite-stable metastatic colorectal cancer. The company reported 33% overall response rate and a 19.5-month median duration of response, and it said investigators and the FDA are discussing an accelerated approval strategy.